Intra-Cellular (ITCI) | Stock Overview & Key Data
Intra-Cellular Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $131.98 on March 31, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2024
Annual Income Flow
2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Intra-Cellular
ITCI
|
14.05B Large-cap | N/A | N/A | N/A | N/A | N/A | 92.68% | 104.13% | 700.67% | 449.92% | 632.61% | 632.61% |
|
Zoetis
ZTS
|
49.75B Large-cap | 0.16% | 3.42% | -31.08% | -32.94% | -36.81% | -51.58% | -53.40% | -57.08% | 71.34% | 156.59% | 156.59% |
|
Haleon Plc - ADR
HLN
|
42.40B Large-cap | 2.02% | 1.23% | -13.29% | -7.73% | -9.30% | -16.01% | 8.43% | 23.21% | 23.21% | 23.21% | 23.21% |
|
United Therapeutics
UTHR
|
25.11B Large-cap | 0.90% | -3.34% | 2.86% | 9.85% | 10.64% | 92.68% | 137.11% | 205.88% | 434.68% | 903.79% | 2,026.01% |
|
Neurocrine
NBIX
|
13.09B Large-cap | -2.21% | 0.69% | 22.84% | 3.54% | 13.45% | 28.43% | 63.69% | 58.93% | 261.12% | 2,094.51% | 952.44% |
|
Viatris
VTRS
|
16.99B Large-cap | 2.45% | -0.97% | 20.80% | 39.97% | 30.98% | 84.75% | 60.16% | 15.57% | -63.39% | -26.00% | -21.07% |
Ownership & Short Interest
Calculate Your Intra-Cellular Investment Returns
Long-Term Investment Performance Analysis
Intra-Cellular stock price in Jul 2016 was $41.30, A $1,000.00 lump sum investment in Intra-Cellular made 8 years ago would be worth approximately $3,192.98 today, representing a outstanding return of 219.30%. This translates to an annualized return (CAGR) of 13.90%.
8 Years 11 Months Investment Scenario (Jul 2016 - Jun 2025)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ITCI's 52-week high and low?
- In the last 52 weeks, Intra-Cellular reached a high of $131.98 (on April 1, 2025) and a low of $64.09 (on May 20, 2024).
- What is the market cap and P/E ratio for ITCI?
- Curious about Intra-Cellular's size and valuation? Its market capitalization stands at 14.05B. When it comes to valuation, the P/E ratio (trailing twelve months) is -183.15, and the forward P/E (looking ahead) is 507.19.
- Does ITCI pay dividends? If so, what's the yield?
- As for dividends, Intra-Cellular isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Intra-Cellular's main competitors or similar companies to consider before investing?
When looking at Intra-Cellular, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS49.75B Healthcare Drug Manufacturers - Specialty & Generic -51.58% -53.40% Haleon Plc - ADR
HLN42.40B Healthcare Drug Manufacturers - Specialty & Generic -16.01% 8.43% United Therapeutics
UTHR25.11B Healthcare Drug Manufacturers - Specialty & Generic 92.68% 137.11% Neurocrine
NBIX13.09B Healthcare Drug Manufacturers - Specialty & Generic 28.43% 63.69% Viatris
VTRS16.99B Healthcare Drug Manufacturers - Specialty & Generic 84.75% 60.16% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Intra-Cellular Therapies Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Intra-Cellular's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -8.58%, the Debt to Equity ratio from the most recent quarter is 1.48, and its Gross Profit Margin stands at 89.76%.
- What is the recent revenue and earnings growth for ITCI?
- Looking at Intra-Cellular's growth, its revenue over the trailing twelve months (TTM) was $681M. Compared to the same quarter last year (YoY), quarterly revenue grew by 50.80%, and quarterly earnings saw a YoY growth of 51.49%.
- How much of ITCI stock is held by insiders and institutions?
- Wondering who owns Intra-Cellular stock? Company insiders (like executives and directors) hold about 2.48% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 96.45%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.